Nadine Rapiti1, Nada Abdelatif2, Anand Rapiti3, Mahomed-Yunus Moosa4. 1. Department of Haematology, NHLS/University of KwaZulu Natal/King Edward VIII Hospital, Durban, South Africa. rapitin@ukzn.ac.za. 2. Biostatistics Research Unit, South African Medical Research Council, Durban, South Africa. 3. Department of Neurosurgery, Inkosi Albert Luthuli Central Hospital, Durban, South Africa. 4. Department of Infectious Diseases, University of KwaZulu-Natal, Durban, South Africa.
Abstract
BACKGROUND: Due to the high prevalence of HIV, HIV-associated lymphoma (HAL) is a common malignancy in South Africa. However, there is a paucity of literature on HAL from this region. The objective of this study was to profile the clinical characteristics and outcome of CD20-positive HAL treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), with or without rituximab (R), from a single center in KwaZulu -Natal, South Africa. METHODS: Retrospective chart review of adult patients treated from 2006 to 2018 for HIV-associated CD20-positive lymphoma. The clinical characteristics, complete response (CR), and 2-year overall survival (OS) are described. RESULTS: The analysis included 102 patients, 54% females, median age of 39 years, and median CD4 cell count of 196 cells/μL. Bone marrow involvement was noted in 5%. Eighty-six percent of the cohort received concomitant antiretroviral therapy and chemotherapy, 76% of the CHOP group, and 92% of the R-CHOP group. Overall, a CR was seen in 55% (95% CI 45%; 65%), with a 2-year OS of 59% (95% CI 50%, 69%). A CR was attained in 46% on CHOP and 64% on R-CHOP, with a 2-year disease-free survival (DFS) for CHOP of 42% and 50% for R-CHOP. CONCLUSION: Although the clinical characteristics and laboratory findings are similar to other higher-income cohorts, there was a difference in gender and incidence of marrow involvement. The low incidence of marrow involvement has prompted more routine use of immunohistochemistry and flow cytometry in staging marrows of HAL locally. Further randomized studies are required for the establishment of locally validated, cost-effective treatment guidelines.
BACKGROUND: Due to the high prevalence of HIV, HIV-associated lymphoma (HAL) is a common malignancy in South Africa. However, there is a paucity of literature on HAL from this region. The objective of this study was to profile the clinical characteristics and outcome of CD20-positive HAL treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), with or without rituximab (R), from a single center in KwaZulu -Natal, South Africa. METHODS: Retrospective chart review of adult patients treated from 2006 to 2018 for HIV-associated CD20-positive lymphoma. The clinical characteristics, complete response (CR), and 2-year overall survival (OS) are described. RESULTS: The analysis included 102 patients, 54% females, median age of 39 years, and median CD4 cell count of 196 cells/μL. Bone marrow involvement was noted in 5%. Eighty-six percent of the cohort received concomitant antiretroviral therapy and chemotherapy, 76% of the CHOP group, and 92% of the R-CHOP group. Overall, a CR was seen in 55% (95% CI 45%; 65%), with a 2-year OS of 59% (95% CI 50%, 69%). A CR was attained in 46% on CHOP and 64% on R-CHOP, with a 2-year disease-free survival (DFS) for CHOP of 42% and 50% for R-CHOP. CONCLUSION: Although the clinical characteristics and laboratory findings are similar to other higher-income cohorts, there was a difference in gender and incidence of marrow involvement. The low incidence of marrow involvement has prompted more routine use of immunohistochemistry and flow cytometry in staging marrows of HAL locally. Further randomized studies are required for the establishment of locally validated, cost-effective treatment guidelines.
Authors: Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht Journal: N Engl J Med Date: 2002-01-24 Impact factor: 91.245
Authors: Eric C Seaberg; Dorothy Wiley; Otoniel Martínez-Maza; Joan S Chmiel; Lawrence Kingsley; Yiwei Tang; Joseph B Margolick; Lisa P Jacobson Journal: Cancer Date: 2010-07-29 Impact factor: 6.860
Authors: Stefan K Barta; Xiaonan Xue; Dan Wang; Roni Tamari; Jeannette Y Lee; Nicolas Mounier; Lawrence D Kaplan; Josep-Maria Ribera; Michele Spina; Umberto Tirelli; Rudolf Weiss; Lionel Galicier; Francois Boue; Wyndham H Wilson; Christoph Wyen; Albert Oriol; José-Tomás Navarro; Kieron Dunleavy; Richard F Little; Lee Ratner; Olga Garcia; Mireia Morgades; Scot C Remick; Ariela Noy; Joseph A Sparano Journal: Blood Date: 2013-09-06 Impact factor: 22.113
Authors: Rudolf Weiss; Paris Mitrou; Keikawus Arasteh; Dirk Schuermann; Marcus Hentrich; Ulrich Duehrsen; Hinrich Sudeck; Ingo G H Schmidt-Wolf; Ioannis Anagnostopoulos; Dieter Huhn Journal: Cancer Date: 2006-04-01 Impact factor: 6.860
Authors: Elias Campo; Steven H Swerdlow; Nancy L Harris; Stefano Pileri; Harald Stein; Elaine S Jaffe Journal: Blood Date: 2011-02-07 Impact factor: 22.113
Authors: Marcus Hentrich; Christian Hoffmann; Franz Mosthaf; Markus Müller; Jan Siehl; Christoph Wyen; Manfred Hensel Journal: Ann Hematol Date: 2014-03-29 Impact factor: 3.673